Pulmonary Function in Patients Recovering From COVID19 Infection : a Pilot Study
- Conditions
- COVID-19
- Interventions
- Diagnostic Test: diaphragm ultrasonography
- Registration Number
- NCT05074927
- Lead Sponsor
- University Hospital, Limoges
- Brief Summary
The current state of knowledge shows the presence of respiratory sequelae after acute infection with COVID-19 and the importance of these long-term respiratory dysfunctions have to be determined.
Aim of our study is describe diaphragmatic amplitude using diaphragm ultrasonography in patients recovering from SARS-CoV-2 pneumonia at 3 and 6 months after the acute episode.
- Detailed Description
patients with confirmed COVID-19 who had been discharged from CHRU Hospital in Limoges (France) will be included to follow the impact of severe acute respiratory syndrom coronavirus 2 on pulmonary function, diaphragm function and exercice capacity. Surviving patients will be evaluated at 3 and 6 months after hospital discharge. The assesment will include diaphragm ultrasonography, spirometry (FEV1,FVC), carbon monoxide transfert (TLCO adjusted for haemoglobin), inspiratory an expiratory respiratory muscle strength (Pimax and Pemax) and 6 minutes walk distance (6MWD).The main outcome will be diaphragm excursion assessed by ultrasound.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 50
- SARS-CoV-2 infection proven by RT-PCR.
- Patient hospitalised for the management of SARS-CoV-2 infection and included 3 months after the end of his hospitalisation at the CHU of Limoges.
- Patient of legal age.
- Patient affiliated to a social security regime.
- Patient having given informed consent
- Known pregnancy.
- Patients who are contraindicated to perform the 6-minute walk test.
- Patients unable to understand or adhere to the protocol.
- Patients deprived of liberty.
- Patients under court order, tutorship or curatorship.
- Minor patients
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Cohort diaphragm ultrasonography All patients with confirmed COVID-19 who had been discharged from CHRU Hospital in Limoges (France)
- Primary Outcome Measures
Name Time Method The change diaphragmatic amplitude using diaphragm ultrasonography in patients recovering from SARS-CoV-2 pneumonia. at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges Diaphragmatic amplitude assessed by ultrasound at M0 and M3.
- Secondary Outcome Measures
Name Time Method the correlation between the values of diaphragmatic travel and Pi max and Pe max at M0 and M3. at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges Diaphragmatic amplitude, PI max and PE max
the difference in diaphragmatic amplitude between M0 and M3. at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges Diaphragmatic amplitude at M0 and M3
the difference in FEV1 between M0 and M3. at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges FEV1 at M0 and M3.
the difference in FVC between M0 and M3. at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges FVC at M0 and M3.
the difference in DLCO between M0 and M3. at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges DLCO at M0 and M3.
the difference in Pi max and Pe max between M0 and M3. at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges PI max and PE max at M0 and M3
dyspnoea between M0 and M3. at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges mMRC dyspnoea scale at M0 and M3.
the functional capacity between M0 and M3. at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges 6-minutes walk test distance at M0 and M3.